These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 21108343)
1. Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients. Song EY; Shin Y; Roh EY; Sue S; Park MH; Kim BH; Kim W; Yoon JH; Lee YJ; Park SJ; Jung EU; Lee JH; Myung SJ; Kim YJ; Lee HS J Med Virol; 2011 Jan; 83(1):88-94. PubMed ID: 21108343 [TBL] [Abstract][Full Text] [Related]
2. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945 [TBL] [Abstract][Full Text] [Related]
3. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort. Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045 [TBL] [Abstract][Full Text] [Related]
4. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222 [TBL] [Abstract][Full Text] [Related]
5. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105 [TBL] [Abstract][Full Text] [Related]
8. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study. Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387 [TBL] [Abstract][Full Text] [Related]
9. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy]. Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242 [TBL] [Abstract][Full Text] [Related]
11. Add-on pegylated interferon augments hepatitis B surface antigen clearance Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352 [TBL] [Abstract][Full Text] [Related]
12. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574 [TBL] [Abstract][Full Text] [Related]
13. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787 [TBL] [Abstract][Full Text] [Related]
14. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655 [TBL] [Abstract][Full Text] [Related]
15. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. He LT; Ye XG; Zhou XY World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369 [TBL] [Abstract][Full Text] [Related]
16. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325 [TBL] [Abstract][Full Text] [Related]
17. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831 [TBL] [Abstract][Full Text] [Related]
18. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. Moucari R; Boyer N; Ripault MP; Castelnau C; Mackiewicz V; Dauvergne A; Valla D; Vidaud M; Chanoine MH; Marcellin P J Viral Hepat; 2011 Aug; 18(8):580-6. PubMed ID: 20487260 [TBL] [Abstract][Full Text] [Related]
19. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B. Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421 [TBL] [Abstract][Full Text] [Related]
20. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]